AI assistant
CONMED Corp — Director's Dealing 2021
Feb 18, 2021
31971_dirs_2021-02-18_43713d3f-a1ea-4836-8a78-5e541410d7b3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CONMED CORP (CNMD)
CIK: 0000816956
Period of Report: 2021-02-16
Reporting Person: TRYNISKI MARK E (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-16 | Common Stock | M | 1000 | $27.63 | Acquired | 43889 | Direct |
| 2021-02-16 | Common Stock | F | 229 | $120.69 | Disposed | 43660 | Direct |
| 2021-02-16 | Common Stock | M | 1000 | $26.09 | Acquired | 44660 | Direct |
| 2021-02-16 | Common Stock | F | 217 | $120.69 | Disposed | 44443 | Direct |
| 2021-02-16 | Common Stock | M | 1000 | $32.93 | Acquired | 45443 | Direct |
| 2021-02-16 | Common Stock | F | 273 | $120.69 | Disposed | 45170 | Direct |
| 2021-02-16 | Common Stock | M | 1000 | $39.64 | Acquired | 46170 | Direct |
| 2021-02-16 | Common Stock | F | 329 | $120.69 | Disposed | 45841 | Direct |
| 2021-02-16 | Common Stock | M | 1000 | $53.83 | Acquired | 46841 | Direct |
| 2021-02-16 | Common Stock | F | 462 | $120.69 | Disposed | 46379 | Direct |
| 2021-02-16 | Common Stock | M | 7195 | $41.06 | Acquired | 53574 | Direct |
| 2021-02-16 | Common Stock | F | 2420 | $122.10 | Disposed | 51154 | Direct |
| 2021-02-16 | Common Stock | S | 2230 | $120.88 | Disposed | 48924 | Direct |
| 2021-02-16 | Common Stock | S | 2545 | $121.31 | Disposed | 46379 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-16 | Sars (Stock Appreciation Rights) | $27.63 | M | 1000 | Disposed | 2021-06-01 | Common Stock (1000) | Direct |
| 2021-02-16 | Sars (Stock Appreciation Rights) | $26.09 | M | 1000 | Disposed | 2022-06-01 | Common Stock (1000) | Direct |
| 2021-02-16 | Sars (Stock Appreciation Rights) | $32.93 | M | 1000 | Disposed | 2023-06-01 | Common Stock (1000) | Direct |
| 2021-02-16 | Sars (Stock Appreciation Rights) | $39.64 | M | 1000 | Disposed | 2024-09-11 | Common Stock (1000) | Direct |
| 2021-02-16 | Sars (Stock Appreciation Rights) | $55.70 | M | 1000 | Disposed | 2025-06-01 | Common Stock (1000) | Direct |
| 2021-02-16 | Options To Purchase Common Stock | $41.06 | M | 7195 | Disposed | 2026-06-01 | Common Stock (7195) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.56 to $121.15. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.21 to $122.11. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
F3: The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 100% after a one year period.
F4: The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting upon completion of the term of service.
F5: The incentive stock options ("ISOs") were granted under the Company's 2016 Amended and Restated Non-Employee Director Equity Compensation Plan and generally vest 100% after a one year period.